Myeloproliferative disorder therapy: assessment and management of adverse events--a psychiatrist's perspective.
Chronic diseases such as the myeloproliferative disorders may mask a worsening emotional state in patients, which can be exacerbated by the addition of common treatments such as interferon-alpha. Management of mood disturbances is best considered from the first consultation, as the negative impact of impaired emotional well-being on physiological outcomes is well established in literature. It is therefore important for physicians to be mindful of their patients' emotional well-being from the point of diagnosis and throughout therapy, and aware of the tendency for physicians to focus on the primary illness. The advice of a psychiatrist may prove useful when discussing management strategies for patients with identifiable mood disturbances.
McDonald
Graeme
G
Mater Hospital, Belfast, UK. aine.shearermih@belfasttrust.hscni.net
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D019468:Disease Management; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects; D009196:Myeloproliferative Disorders / Q000188:drug therapy / Q000523:psychology*; D011570:Psychiatry / Q000379:methods*; D018570:Risk Assessment
D000970:Antineoplastic Agents; D016898:Interferon-alpha